This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Overall, Palantir's software is helping to improve patient care, accelerate research, and improve drugdevelopment. Palantir's products are helping these organizations to improve patient care, accelerate research, and improve drugdevelopment. What are a few likely scenarios for Palantir in Healthcare? Have a comment?
the leading technology provider for modern clinical trials, announces results from a new research project with Duke University Department of Population HealthSciences’ Bioethics and Stakeholder (BASE) Lab on the acceptability of enhanced electronic informed consent (eIC) in clinical trials. .–(BUSINESS WIRE)–Medable Inc.,
Overall, Palantir's software is helping to improve patient care, accelerate research, and improve drugdevelopment. Palantir's products are helping these organizations to improve patient care, accelerate research, and improve drugdevelopment. What are a few likely scenarios for Palantir in Healthcare?
A Tufts Center for the Study of DrugDevelopment study shows that, on average, decentralized trials can achieve net financial benefits from five to 13 times for Phase II and Phase III trials, equating to roughly $10 million ROI and $39 million ROI for an investment on average of $500K in Phase II and $1.5M
Aviceda Glycotech looks forward to this collaboration aimed at developing the next generation of cancer checkpoint immune therapeutics in Belfast. “It Co-Founder & President, and Chief Executive Officer. This commercial investment is testament to collaboration across the island of Ireland and the US.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content